Alternative splicing of platelet cyclooxygenase-2 mRNA in patients after coronary artery bypass grafting

被引:14
作者
Censarek, Petra [2 ]
Steger, Gerhard [3 ]
Paolini, Carla [2 ]
Hohlfeld, Thomas [2 ]
Grosser, Tilo [4 ,5 ]
Zimmermann, Norbert [6 ]
Fleckenstein, Diana [1 ]
Schroer, Karsten [2 ]
Weber, Artur-Aron [1 ]
机构
[1] Univ Duisburg Essen, Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany
[2] Univ Klinikum Duesseldorf, Inst Pharmakol & Klin Pharmakol, Dusseldorf, Germany
[3] Univ Dusseldorf, Inst Phys Biol, D-4000 Dusseldorf, Germany
[4] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA
[6] Bundesinst Arzneimittel & Med Prod, Bonn, Germany
关键词
platelet COX-2; COX-2a; aspirin; thromboxane; CABG; qPCR;
D O I
10.1160/TH07-05-0346
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, we cloned from platelet mRNA a novel cyclooxygenase (COX)-2 splice variant, designated COX-2a, which is characterized by a partial deletion of exon 5.Preliminary studies of mRNA distribution of COX-2 isoforms in platelets from coronary artery bypass grafting (CABG) patients showed a variable increase in COX-2a mRNA expression after cardiac surgery.Thus, we assessed whether this variant may play a functional role in these patients.We report a marked (about 200-fold) increase in the expression of COX-2a mRNA after CABG. Evidence is presented that ribosomal frame-shifting may correct the coding sequence resulting in the expression of a full-length COX-2a protein. In addition, a reading frame-corrected COX-2a mutant (COX-2a Delta G) was generated by site-directed mutagenesis and expressed in COS-7 cells using an adenoviral expression system. However, COX-2a protein was not active in terms of prostaglandin formation. Thus, alternative mRNA splicing might represent an intriguing posttranscriptional mechanism to oppose a transcriptional activation of the COX-2 gene. Evolutionary, this mechanism may prevent COX-2-dependent thromboxane synthesis in the platelet, which would potentiate the likelihood of thrombosis; pharmacologically, this mechanism would prevent an aspirin-insensitive pathway of thromboxane formation.
引用
收藏
页码:1309 / 1315
页数:7
相关论文
共 39 条
  • [1] LOW ACTIVITY OF BETA-GALACTOSIDASE IN FRAMESHIFT MUTANTS OF ESCHERICHIA-COLI
    ATKINS, JF
    ELSEVIERS, D
    GORINI, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1972, 69 (05) : 1192 - +
  • [2] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [3] Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting
    Censarek, P
    Freidel, K
    Udelhoven, M
    Ku, SJ
    Hohlfeld, T
    Meyer-Kirchrath, J
    Schrör, K
    Weber, AA
    [J]. THROMBOSIS AND HAEMOSTASIS, 2004, 92 (05) : 925 - 928
  • [4] Human cyclooxygenase-1b is not the elusive target of acetaminophen
    Censarek, Petra
    Freidel, Kerstin
    Hohfeld, Thomas
    Schroer, Karsten
    Weber, Artur-Aron
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 551 (1-3) : 50 - 53
  • [5] COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression
    Chandrasekharan, NV
    Dai, H
    Roos, KLT
    Evanson, NK
    Tomsik, J
    Elton, TS
    Simmons, DL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) : 13926 - 13931
  • [6] Role of prostacyclin in the cardiovascular response to thromboxane A2
    Cheng, Y
    Austin, SC
    Rocca, B
    Koller, BH
    Coffman, TM
    Grosser, T
    Lawson, JA
    FitzGerald, GA
    [J]. SCIENCE, 2002, 296 (5567) : 539 - 541
  • [7] DIMINNO G, 1983, BLOOD, V61, P1081
  • [8] MECHANISMS OF PLATELET ACTIVATION - THROMBOXANE-A2 AS AN AMPLIFYING SIGNAL FOR OTHER AGONISTS
    FITZGERALD, GA
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (07) : B11 - B15
  • [9] Structure, stability and function of RNA pseudoknots involved in stimulating ribosomal frameshifting
    Giedroc, DP
    Theimer, CA
    Nixon, PL
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2000, 298 (02) : 167 - 185
  • [10] Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
    Grosser, T
    Fries, S
    FitzGerald, GA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) : 4 - 15